Convertible Promissory Note Receivable
|3 Months Ended|
Sep. 30, 2022
|Convertible Promissory Note Receivable [Abstract]|
|Convertible Promissory Note Receivable||
7. Convertible Promissory Note Receivable
On October 1, 2020, the Company entered into a master services agreement with Safi Biosolutions, Inc. (“Safi”). In addition, the Company invested $1.5 million in Safi in the form of a convertible promissory note (the "Note"). The Note bears interest at the rate of 5% per annum and is convertible into shares of Safi’s common stock (as defined). Principal and accrued interest mature on October 1, 2023. For both of the three months ended September 30, 2022 and 2021, interest income amounted to $19,000. As of September 30, 2022 and June 30, 2022, the Note balance and accrued interest totaled $1,650,000 and $1,631,000, respectively.
The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef